Global Information
회사소개 | 문의 | 비교리스트

협심증 : 파이프라인 제품 분석

Angina (Angina Pectoris) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 219722
페이지 정보 영문 78 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


협심증 : 파이프라인 제품 분석 Angina (Angina Pectoris) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 78 Pages

협심증은 심근허혈(심근에 보내지는 산소량이 충분하지 않은 상태)에 의해 가슴에 통증이 생기는 상태를 가리키는 말입니다. 일반적으로 몸을 움직였을 때(노동) 때에 발생하며, 안정을 취하면 회복됩니다. 일반적으로 편도선이 관상 동맥 질환의 증후가 되고 있습니다. 그러나 가장 중독한 경우는 아주 약간 움직였거나 안정을 취할 때에도 발작이 발생합니다. 위험요인에는 흡연과 좌식 생활습관, 고지혈증, 고콜레스테롤 혈증 등이 있습니다. 주요 증상으로 불안증과 심박수 상승 또는 불안정, 안면 창백, 식은 땀, 우울한 기분 등이 있습니다. 이러한 증상은 심장 발작의 증상과도 비슷합니다.

세계 각국에서의 협심증(Angina, Angina Pectoris) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

협심증 개요

치료제 개발

  • 협심증용 파이프라인 제품 : 개요
  • 협심증용 파이프라인 제품 : 기업별
  • 개발중인 협심증용 제품 목록 : 기업별

협심증 : 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 방법별
  • 분자 종류별

협심증 치료제 개발 참여 기업

  • Angionetics Inc
  • Juventas Therapeutics, Inc.
  • Kuhnil Pharmaceutical Co., Ltd.
  • Sanofi.
  • TSH Biopharm Corporation Ltd
  • ViroMed Co., Ltd.
  • XyloCor Therapeutics Inc

약제 개요

협심증 치료제 : 개발 휴지 상태인 제품

협심증 치료제 : 개발이 중지된 제품

협심증 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

LSH 17.10.25

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Angina (Angina Pectoris), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by VasThera Research Institute, H1 2020
  • Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H1 2020
  • Angina (Angina Pectoris) - Dormant Projects, H1 2020
  • Angina (Angina Pectoris) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Angina (Angina Pectoris) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Angina (Angina Pectoris), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 2, 3, 4 and 3 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Angina (Angina Pectoris) - Overview
    • Angina (Angina Pectoris) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Angina (Angina Pectoris) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
    • Angionetics Inc
    • Ark Therapeutics Ltd
    • Caladrius Biosciences Inc
    • G. Pohl-Boskamp GmbH & Co KG
    • Hemostemix Inc
    • Imbria Pharmaceuticals Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Kuhnil Pharmaceutical Co Ltd
    • Milestone Pharmaceuticals Inc
    • Signal Pharma Ltd
    • TSH Biopharm Corporation Ltd
    • VasThera Research Institute
    • XyloCor Therapeutics Inc
  • Angina (Angina Pectoris) - Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alferminogene tadenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-16 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EG-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etripamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMB-1018972 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ivabradine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KI-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitroglycerin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranolazine ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Angina - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Angina (Angina Pectoris) - Dormant Projects
  • Angina (Angina Pectoris) - Discontinued Products
  • Angina (Angina Pectoris) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
      • Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
      • Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction
      • Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
      • Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
      • Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
      • Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
      • Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
      • Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
      • Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
      • May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
      • Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
      • Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
      • May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
      • Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q